Annette Koerner

Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia

J. Dukart, M. Cappellini, C. Brugnara, 2021, British journal of haematology.

Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of beta-thalassemia.

A. Iolascon, A. Mattè, L. De Franceschi, 2019, JCI insight.

Cardiovascular safety assessments in the cynomolgus monkey: Unmasking potential background arrhythmias in general toxicity studies.

T. Baird, Annette Koerner, A. Greiter-Wilke, 2016, Journal of pharmacological and toxicological methods.

Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants

Thomas Singer, Neil Parrott, Thierry Lave, 2011, Clinical pharmacokinetics.

Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.

Annette Koerner, P. Barrow, N. Parrott, 2016, Birth defects research. Part B, Developmental and reproductive toxicology.

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

M. Britschgi, C. Rayner, Annette Koerner, 2012, Advances in Therapy.

Phase 2 Clinical Trial Results for Bitopertin, an Oral Glycine Transporter 1 Inhibitor, in Patients with Non-Transfusion Dependent Beta-Thalassemia

J. Dukart, M. Cappellini, S. Nave, 2018, Blood.

Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.

E. Pinard, D. Umbricht, E. Borroni, 2018, Chimia.